A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result
The ideal candidate for semadrops: Has no previous cases of severe low blood sugar Doesnt have a current or past diagnosis of thyroid cancer Has no endocrine system issues Is free from gallbladder problems Isnt pregnant or breastfeeding At The Gallery of Cosmetic Surgery, our providers evaluate each patient thoroughly to determine their qualifications for semaglutide use
Nadelmans practice, we are dedicated to providing personalized care and support throughout your healthcare journey
Especially with diabetes, which has been devouring employer budgets at twice the rate of everything else
This article explains where the 3 mg dose fits, what patients commonly discuss at this stage, and why dosing should always follow the specific FDA-approved label and the prescribing providers instructions